Sulfotransferase genetic variation: from cancer risk to treatment response

Daniels, Jaclyn; Kadlubar, Susan

doi:10.3109/03602532.2013.835621

Cited by 35 publications

(23 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, depending on the xenobiotic, the quercetin dose, the duration of exposure and/or the timing of exposure, quercetin may increase or decrease the bioavailability of xenobiotics due to its impact on the expression and activity of xenobiotic metabolising enzymes or on transport proteins. However, there are sometimes conflicting results regarding specific enzyme activations or inhibitions which may be due to differences in the species, gender, race, sample size, genetic variations, molecular heterogeneity of cancer and genotyping methodologies …”

Section: Safety Aspectsmentioning

confidence: 99%

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Andres

Pevny

Ziegenhagen

et al. 2017

Molecular Nutrition Food Res

413

246

View full text Add to dashboard Cite

The flavonoid quercetin is frequently found in low amounts as a secondary plant metabolite in fruits and vegetables. Isolated quercetin is also marketed as a dietary supplement, mostly as the free quercetin aglycone, and frequently in daily doses of up to 1000 mg d -1 exceeding usual dietary intake levels. The present review is dedicated to safety aspects of isolated quercetin used as single compound in dietary supplements. Among the numerous published human intervention studies, adverse effects following supplemental quercetin intake have been rarely reported and any such effects were mild in nature. Published adequate scientific data for safety assessment in regard to the long-term use (>12 weeks) of high supplemental quercetin doses (ࣙ1000 mg) are currently not available. Based on animal studies involving oral quercetin application some possible critical safety aspects could be identified such as the potential of quercetin to enhance nephrotoxic effects in the predamaged kidney or to promote tumor development especially in estrogen-dependent cancer. Furthermore, animal and human studies with single time or short-term supplemental quercetin application revealed interactions between quercetin and certain drugs leading to altered drug bioavailability. Based on these results, some potential risk groups are discussed in the present review.

show abstract

Section: Safety Aspectsmentioning

confidence: 99%

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Andres

Pevny

Ziegenhagen

et al. 2017

Molecular Nutrition Food Res

413

246

View full text Add to dashboard Cite

show abstract

“…As a result of rapid advance in genomic technologies, genetic variants have been demonstrated by previous studies as potential factors that may affect both cancer etiology [6] and patients’ response to therapies [7] . For example, single nucleotide polymorphisms (SNPs), presented more than 1% in the general population, have been reported to be associated with GCa risk [8–10].…”

Section: Introductionmentioning

confidence: 99%

Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients?

et al. 2016

View full text Add to dashboard Cite

Literature suggests that genetic variants associated with increased susceptibility to gastric cancer (GCa) are mostly located in genes involved in carcinogenesis and possibly tumor progression. Therefore, we hypothesize that high genetic susceptibility is also associated with prognosis of the patients. To test this hypothesis, we selected a total of 42 common genetic variants that were reportedly associated with GCa risk with a high level of evidence obtained from either genome-wide association studies (GWASs) or meta-analyses and performed survival analysis of patients used in a case-control analysis. We first used 1115 GCa cases and 1172 cancer-free controls of ethnic Han Chinese to construct a weighted genetic risk score (GRS). Then, we included 633 GCa cases with available clinical information, fit GRS in a fractional polynomial Cox proportional hazards regression model to investigate whether there is a dose-dependent effect of GRS on risk of death in survival analysis. Dynamic predictive value of genetic risk for prognosis was also calculated. The results showed that the increase of GRS had no effect on risk of death in these GCa patients. Compared with GCa patients with the medium GRS, there was no significant difference in survival in patients with either a low (P = 0.349) or a high (P = 0.847) GRS. The results unchanged when data were stratified by tumor stage and Laurens classification. Time-dependent predictive value for prognosis in considering both clinical factors and GRS was comparable with that in considering clinical factors alone, for either all patients (P = 0.986) or stage- and Laruen type-based subgroups (P > 0.05 for all). In conclusion, higher polygenic susceptibility loci for GCa may not indicate worse prognosis of Chinese patients. Additional variants of relevant genes modulating GCa patients survival need to be further identified.

show abstract

“…Moreover, in view of the individual differences in susceptibility to the adverse effects of ritodrine, it is an intriguing issue whether SULT genetic polymorphism may affect the metabolism of ritodrine through sulfation. Like with many other genes, single nucleotide polymorphisms (SNPs) of SULT genes have been reported (Glatt et al, 2000; Lindsay et al, 2008; Daniels and Kadlubar, 2013). For example, four non-synonymous coding SNPs (cSNPs) for the SULT1A3 gene were detected by sequencing DNA samples from African-American and Caucasian-American subjects (Thomae et al, 2003; Hildebrandt et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): Effects of SULT1A3 genetic polymorphism

Hui

Liu

2015

European Journal of Pharmacology

View full text Add to dashboard Cite

Previous studies have demonstrated the metabolism of ritodrine through sulfation. The current study was designed to identify the human SULTs that are capable of sulfating ritodrine and to investigate how genetic polymorphism of the major ritodrine-sulfating SULT, SULT1A3, may affect its sulfating activity. A systematic analysis revealed that of the 13 known human SULTs, SULT1A1, SULT1A3, and SULT1C4, were capable of mediating the sulfation of ritodrine, with SULT1A3 displaying the strongest sulfating activity. Effects of genetic polymorphism on the sulfating activity of SULT1A3 were examined. By employing site-directed mutagenesis, 4 SULT1A3 allozymes were generated, expressed, and purified. Purified SULT1A3 allozymes were shown to exhibit differential sulfating activity toward ritodrine. Kinetic studies further demonstrated differential substrate affinity and catalytic efficiency among the SULT1A3 allozymes. Collectively, these results provided useful information concerning the differential metabolism of ritodrine through sulfation in different individuals.

show abstract

Sulfotransferase genetic variation: from cancer risk to treatment response

Cited by 35 publications

References 77 publications

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Safety Aspects of the Use of Quercetin as a Dietary Supplement

Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients?

Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): Effects of SULT1A3 genetic polymorphism

Contact Info

Product

Resources

About